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CD28 and CTLA-4 are cell surface cosignaling mole-
cules essential for the control of T cell activation
upon the engagement of their ligands B7-1 and
B7-2 from antigen-presenting cells. By employing
a receptor array assay, we have demonstrated that
B7-H2, best known as the ligand of inducible costi-
mulator, was a ligand for CD28 andCTLA-4 in human,
whereas these interactions were not conserved in
mouse. B7-H2 and B7-1 or B7-2 interacted with
CD28 through distinctive domains. B7-H2-CD28
interaction was essential for the costimulation of
human T cells’ primary responses to allogeneic anti-
gens and memory recall responses. Similar to B7-1
and B7-2, B7-H2 costimulation via CD28 induced
survival factor Bcl-xL, downregulated cell cycle
inhibitor p27kip1, and triggered signaling cascade of
ERK and AKT kinase-dependent pathways. Our find-
ings warrant re-evaluation of CD28 and CTLA-4’s
functions previously attributed exclusively to B7-1
and B7-2 and have important implications in thera-
peutic interventions against human diseases.
INTRODUCTION
The B7-CD28 family of costimulatory molecules modulates T cell
receptor signals and plays essential roles in the control of T cell-
mediated immune responses (Carreno and Collins, 2002; Chen,
2004). CD28, the most extensively studied cosignaling receptor,
accepts a costimulatory signal from B7-1 (CD80) or B7-2 (CD86,
B70) and promotes activation of naive T cells in the presence of
a T cell receptor signal (Linsley et al., 1990). On the other hand,
CTLA-4, a CD28 homolog expressed on activated T cells, serves
as a checkpoint to attenuate T cell responses upon ligation of
B7-1 and/or B7-2 (Krummel and Allison, 1995; Walunas et al.,
1994). Inducible costimulator (ICOS), another CD28 homolog in
the same gene cluster with CD28 and CTLA4, is expressed on
activated T cells and costimulates T cell activation upon binding
of a distinct ligand B7-H2 (ICOSLG, GL50, B7RP1, CD275,
ICOSL, LICOS) (Hutloff et al., 1999; Swallow et al., 1999; Wang
et al., 2000; Yoshinaga et al., 1999).
Although CD28 and ICOS have distinct intracellular domains,
they share a great functional redundancy, including their
capacity to costimulate growth, survival, and differentiation ofT cells, as well as the requirement for antibody response (Dong
et al., 2001; Linterman et al., 2009; McAdam et al., 2001; Tafuri
et al., 2001). Both CD28 and ICOS signals are shown to have
similar capacity in costimulating an array of cytokines, including
interleukin-4 (IL-4), interleukin-5 (IL-5), interferon-g (IFN-g), and
tumor necrosis factor-a (TNF-a) (Hutloff et al., 1999). The main
difference between CD28 and ICOS pathways is that CD28
induces high amounts of IL-2 and upregulates survival factor
Bcl-xL (Boise et al., 1995; Parry et al., 2003), whereas ICOS pref-
erentially costimulates IL-10 (Hutloff et al., 1999). These findings
are consistent with observations in the microarray analysis of
T cell transcription profiles, which show highly similar patterns
upon costimulation by both CD28 and ICOS, especially in human
T cells (Riley et al., 2002).
A possible explanation for the functional redundancy of
these two distinct costimulatory pathways is the presence of
a shared ligand. Even though the interaction between the puta-
tive ligand and CD28 may be well below the detectable level
by conventional binding technology, it is still sufficient to trigger
T cell functions. In order to detect interactions of these cell
surface proteins, we established a highly sensitive, comprehen-
sive receptor array coupled with a high-throughput screening
system. With this methodology, we re-evaluated possible
receptor-ligand interactions in the CD28 and ICOS molecular
pathways.RESULTS
Identification of B7-H2-CD28 Interaction
by a Receptor Array
We selected more than 2000 full-length human transmembrane
genes based on their immune and hematopoietic cell surface
expression (Table S1 available online). All of these genes were
cloned into mammalian expression vectors. Each individual
plasmid was introduced into 293T cells in a 384-well plate format
by an optimized transfection protocol. More than 95% of the
genes from randomly selected plasmids in our collection
expressed highly on the cell surface, which was confirmed by
flow cytometry analysis (data not shown). For screening
unknown counter-receptors, the target gene (encoding
a secreted protein) or the extracellular domain of the target
gene (encoding a transmembrane protein) was genetically fused
to a tag gene (mouse IgG2a Fc, human IgG1 Fc, FLAG, or 6xHIS),
and the purified recombinant fusion protein was used to bind the
receptor array. A fluorescence-labeled secondary antibody
against the tag was applied to detect the binding of the targetImmunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc. 729
Figure 1. Identification of B7-H2-CD28
Interaction by High Throughput Screening
of a Receptor Array
(A) Screening of additional ligands for CD28 in
a receptor array. CD28Ig was used as bait in the
screening system. The 3D illustration represents
the result of a set of five 384-well plates. Each bar
represents the total fluorescence intensity in the
FL1 gate in each well of a 384-well plate. The Fc
receptor transfectants are used as positive
controls.
(B) Interactions among B7-CD28 family mole-
cules. 293T cells were transfected with full-length
human B7-CD28 family genes as indicated on the
x axis. Fusion proteins were added to the culture
as indicated on the y axis to evaluate their bindings
to the transfectants by CDS. Graphic view of
individual wells is captured by 8200 CDS.
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Applied Biosystems 8200 Cellular Detection System (CDS).
Because our receptor array approach has better sensitivity for
detection of molecular interactions than other methods, we first
screened recombinant human CD28-immunoglobulin (CD28Ig)
fusion proteins for system validation and for additional ligands
(Figure 1A). As expected, CD28Ig bound 293T cells expressing
B7-1 or B7-2 genes in the array. The cells expressing Fc recep-730 Immunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc.tors, used as internal controls, also
stained positive because of the binding
of the human Fc tag on CD28Ig. To our
surprise, CD28Ig was found to bind cells
expressing B7-H2, albeit with a lower
affinity than B7-1 and B7-2 transfectants
(Figures 1A and 1B). The binding activity
to tight junction adhesion molecule
occludin (OCLN) was also found but
this interaction was demonstrated to be
nonspecific (data not shown). There was
no additional binding activity by CD28Ig
in our receptor array. Therefore, CD28
and ICOS may share a common ligand,
B7-H2.
Specificity of B7-H2 Interactions
with CD28 and CTLA-4
We first validated the B7-H2-CD28 inter-
action by using CD28Ig to stain B7-H2
transiently transfected 293T cells via
flow cytometry analysis. High B7-H2
expression was verified by positive stain-
ing of B7-H2 monoclonal antibody (mAb)
and negative staining of B7-1 and
B7-2 mAbs (Figure 2A). The majority of
cells also stained positively by ICOSIg,
demonstrating the specific expression
of B7-H2 on 293T cells. Importantly,
CD28Ig showed strong binding to B7-
H2+ 293T cells, and this binding was
completely blocked by the inclusion ofa mAb against CD28 (clone CD28.6). Both B7-1 and B7-2 bind
CTLA-4 in addition to CD28, so we subsequently tested whether
B7-H2 could interact with CTLA-4. CTLA-4Ig also bound B7-H2+
293T cells (Figure 1C), and the bindingwas largely abolished by a
mAb against CTLA-4 (clone 14D3) (Figure 2A). To further confirm
these additional interactions, we transiently transfected 293T
cells to express high amounts of CD28 or CTLA-4, as shown
by respective mAb staining (Figures 2B and 2C). B7-H2Ig bound
Figure 2. B7-H2 Binds Both CD28 and CTLA-4
(A–C) Specificity of B7-H2 bindings to CD28 and CTLA-4. 293T cells were transiently transfected with human full-length B7-H2 (A), CD28 (B), or CTLA-4 (C)
plasmids and were subsequently stained by the indicated specific mAb or fusion proteins. In some experiments, additional mAb or fusion proteins were also
included to examine the specificity of the binding. CD28.6 is a mAb to human CD28; 14D3 is a mAb to human CTLA-4; and MIH12 is a mAb to human B7-H2.
(D) Murine B7-H2 does not interact with murine CD28 and CTLA-4, although human B7-H2 interacts with murine ICOS, CD28, and CTLA-4. 293T cells were
transiently transfected with mouse full-length B7-H2, a hB7-H2IgV-mB7-H2 chimeric construct, or human full-length B7-H2 plasmids and were stained by the
indicated fusion proteins.
(E) Interactions of CD28 andCTLA-4 with their three ligands. To examine the competition between B7-H2 and B7-1 or B7-2 for binding CD28 andCTLA-4, B7-H2+
293T cell transfectants were stained by CD28Ig and CTLA-4Ig, which were preincubated with excessive amount of B7-1Ig or B7-2Ig. Isotype-matched human Ig
(Ctl Ig) were included as controls.
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fusion proteins. Inclusion of a mAb against B7-H2 (clone
MIH12) or ICOSIg completely abrogated these interactions
(Figures 2B and 2C). The binding of dimeric CD28 and CTLA4
Ig fusion protein to immobilized B7-H2 was also validated by
surface plasmon resonance (SPR) analysis at both 25C and
37C (Figure S1). Altogether, our data support the specificity ofB7-H2-CD28 and B7-H2-CTLA-4 interactions and indicate an
overlapping binding site on B7-H2 for interacting with ICOS,
CD28, and CTLA-4.
We next examined whether these additional interactions were
also conserved in mice. Both murine CD28Ig and CTLA-4Ig did
not stain murine B7-H2-transfected 293T cells by flow cytometry
analysis, whereas ICOSIg bound the transfectant as expectedImmunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc. 731
Figure 3. Interactions of B7-H2 with CD28,
CTLA-4, and ICOS
(A) Left: Ribbon diagram modeling the interaction
between B7-H2 and ICOS, CD28, or CTLA-4. The
model was built by Pymol software (DeLano
Scientific, LLC) based on the crystal structure of
B7-2-CTLA-4 (RCSBPDB 1i85). Right: binding site
analysis of B7-H2 with its receptors by site-
directed mutagenesis. Single point mutations
were introduced into B7-H2 residues buried at
the ligand-receptor interacting interface (shown
in purple in ribbon diagram). B7-H2 plasmids
(wild-type and mutants) were then transiently
transfected into 293T cells and the expression of
B7-H2 was confirmed by B7-H2 antibody staining.
Binding of human ICOSIg, CD28Ig, and CTLA-4Ig
to B7-H2 mutants in transfected cells were
measured by flow cytometry and normalized
against 293T cells expressing wild-type B7-H2
(100%) and vector control (0%). The results were
expressed as the percentage of binding to wild-
type B7-H2. In addition to the mean (n = 3), 95%
confidence intervals were given for each binding.
(B and C) CTLA-4 competes with CD28 for B7-H2
binding.
(B) CTLA-4Ig (Abatacept) was used to stain B7-
H2+ 293T cells.
(C) B7-H2Ig was preincubated with an excessive
amount of Abatacept or control Ig for 15 min
before staining CD28+ 293T cells.
(D) Identification of mAbs that differentially abro-
gate B7-H2-CD28 and B7-H2-ICOS interactions.
ICOS+, CD28+, or CTLA-4+ 293T cell transfectants
were stained by B7-H2Ig or control (ctl) Ig. B7-H2
mAbs MIH12, 9F.8A4, or control mouse Ig were
included in the cultures to examine their blocking
effects on B7-H2Ig binding.
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was replaced with its corresponding human counterpart (Met1-
Gln123), this chimeric B7-H2 was capable of binding murine
CD28 and CTLA-4 (Figure 2D), indicating that interactions of
B7-H2 with CD28 and CTLA-4 are not conserved in mice. Similar
to the chimeric protein, wild-type human B7-H2Ig could also
bind the cells transfected to express murine CD28 and CTLA-4
(Figure 2D).
We next addressed the question of whether B7-H2 could
compete with B7-1 and B7-2 for binding CD28. Flow cytometry
analysis showed that saturated doses of B7-1Ig and B7-2Ig had
only minimal effect on the binding of CD28Ig to B7-H2+ 293T
cells (Figure 2E). Therefore, CD28 binds B7-H2 and B7-1 or
B7-2 through different interfaces, suggesting that B7-H2 and
B7-1 or B7-2 could bind CD28 simultaneously. A similar test
examined the interactions of the three ligands to CTLA-4. Inter-
estingly, saturated B7-2Ig but not B7-1Ig partially blocked the
binding of CTLA-4Ig to B7-H2+ 293T cells (Figure 2E), indicating
that the binding sites on CTLA-4 for B7-H2 and B7-2 may
overlap.732 Immunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc.B7-H2 Utilizes Overlapping but Different Binding Sites
to Interact with ICOS, CD28, and CTLA-4
To understand the architecture of the interactions between
B7-H2 and its three receptors, we conducted site-directed
mutagenesis on B7-H2 to identify critical residues for the three
interactions. Selection of residues for mutation was based on
their locations in the binding interfaces of B7-H2 and three
receptors predicted from the crystal structure of B7-2-CTLA-4
(Figure 3A, left; Chattopadhyay et al., 2006; Schwartz et al.,
2001). These residues were all converted to alanine, a small
amino acid with neutral charge, to avoid a large overall structure
modulation (Chattopadhyay et al., 2006). Wild-type and mutated
B7-H2 full-length genes were expressed on the surface of 293T
cells and confirmed by anti-B7-H2 staining. The binding of
these cells by CD28Ig, CTLA-4Ig, and ICOSIg were determined
by flow cytometry analysis. The relative binding capacity of these
recombinant fusion proteins to B7-H2 mutants were compared
with wild-type B7-H2 (Figure 3A, right). All mutants, which lost
their binding to CD28 (Y51A, Y53A, L116A, and F122A), also
did not interact with CTLA-4, indicating that B7-H2’s binding
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CTLA-4 should compete for the binding to B7-H2. Indeed, CTLA-
4Ig (Abatacept) bound B7-H2+ 293T cells (Figure 3B) and
completely blocked B7-H2Ig binding to CD28+ 293T cells
(Figure 3C).
Two mutants (Y51A, Y53A) that lost their binding to ICOS also
showed no binding to CD28 and CTLA-4. Interestingly, two
mutants (L116A and F122A) that largely retained the ability to
bind ICOS had only minimal binding capacity to CD28 and
CTLA-4 (Figure 3A, right). These results support that B7-H2
uses overlapping but different domains to interact with ICOS
versus CD28 and CTLA-4, whereas its binding sites for CD28
and CTLA-4 are very similar.
The finding that B7-H2 utilizes overlapping but differential
binding sites to interact with ICOS versus CD28 and CTLA-4
encouraged us to seek B7-H2 mAbs that selectively block indi-
vidual interactions to facilitate functional analysis. As shown in
Figure 3D, mAb clone MIH12 specifically blocked B7-H2Ig
binding to CD28+ and CTLA-4+ 293T cells but had no effect on
B7-H2Ig binding to ICOS+ 293T cells, whereas mAb clone
9F.8A4 abrogated B7-H2Ig binding to all three receptors by
flow cytometry analysis (Figure 3D). We have not yet identified
a mAb that specifically blocks B7-H2 binding to CD28 but not
to CTLA-4 and vice versa (data not shown) and this may be
due to the fact that B7-H2 binding sites for CD28 and CTLA-4
are largely overlapping (Figure 3A).
B7-H2 Costimulates Human T Cell Proliferation
and Cytokine Production via CD28
In an initial attempt to demonstrate a functional interaction of
B7-H2 and CD28, we utilized an in vitro costimulation assay in
which suboptimal concentrations of human CD3 mAb were
immobilized in a 96-well plate mimicking T cell receptor (TCR)
signaling. B7-H2Ig was coimmobilized in the same well to
provide a costimulatory signal for purified human T cells.
Whereas suboptimal concentrations of CD3 mAb (up to
0.1 mg/ml) led to minimal proliferation of T cells, inclusion of
B7-H2Ig in the wells induced strong T cell proliferation as
evidenced by increased incorporation of tritiated thymidine
(Figure 4A). The effect of B7-H2was dependent on TCR signaling
because B7-H2Ig alone, in the absence of CD3 mAb, did not
stimulate any detectable proliferation (data not shown). Inclusion
of mAb MIH12, which specifically blocks B7-H2 binding to
CD28 and CTLA-4 but not to ICOS, suppressed about 50% of
B7-H2Ig-mediated costimulation. The mAb 9F.8A4, which
blocks B7-H2 binding to all three receptors, completely abol-
ished the effect of B7-H2Ig (Figure 4A). Similar results were
acquired from different donors (Figure S2). Accordingly, CD28
mAb (clone CD28.6) partially inhibited B7-H2-mediated T
proliferation, whereas ICOS mAb (C398.4A) suppressed the
majority of the B7-H2 costimulatory effect. Complete inhibition
was achieved with a combination of CD28 and ICOS mAbs
(Figure 4B).
Next we assessed the costimulatory capacity of B7-H2mutant
fusion proteins. B7-H2 L116A and F122A mutants largely main-
tained binding to ICOS, but not to CD28 and CTLA-4, whereas
the Y51A mutant lost binding capacity to all three receptors (Fig-
ure 3A). L116A and Y51A could no longer costimulate T cell
proliferation as wild-type B7-H2 and Q123A did (Figure S3).Meanwhile, F122A also lost the majority of its costimulatory
capacity, indicating that the B7-H2 interface for CD28 interaction
is important for B7-H2 function.
We also used carboxyfluorescein succinimidyl ester (CFSE)-
labeled human T cells to monitor cell division. The blockade of
the B7-H2-CD28 interaction with MIH12 had a partial inhibitory
effect on the division of both CD4+ and CD8+ T cells, whereas
9F.8A4 completely suppressed T cell division (Figure 4C), a result
consistent with the thymidine incorporation assay. Activated
T cells in this setting expressed high amounts of ICOS in addition
to CD28 (data not shown). Because CTLA-4 did not play a domi-
nant role in this assay, we conclude that ligations of B7-H2 to
both CD28 and ICOS on T cells independently contribute to
the costimulatory function of B7-H2 in this assay. Therefore,
B7-H2 could promote T cell growth by engaging CD28.
One characteristic feature of CD4+ T cell costimulation
through both CD28 and ICOS is to induce large amounts of cyto-
kines, in contrast to TCR engagement alone, which produces
minimal cytokines (Hutloff et al., 1999). We first compared cyto-
kine profiles induced by B7-1Ig versus B7-H2Ig in the same
concentration employing a cytokine array (Figure S4). Consistent
with previous finding using CD28 and ICOS agonist mAbs (Riley
et al., 2002), costimulation through B7-1 and B7-H2 induced an
overlapping spectrum of cytokines including TNF-a, IFN-g, IL-4,
IL-5, IL-10, and IL-17A. Only B7-1Ig stimulated a large amount of
IL-2 (100-fold higher than B7-H2Ig). B7-1 also elicited higher
amounts of TNF-a and IFN-g, and B7-H2 appeared to induce
more IL-17A (Figure S4). We did not observe a superior ability
of B7-H2Ig in the stimulation of IL-10 production in our assay
over 3 days, as shown previously by an ICOS agonist mAb
(Hutloff et al., 1999).
In the context of the overlapping cytokine profile induced by
B7-1 and B7-H2, we evaluated the relative contribution of
B7-H2-CD28 versus B7-H2-ICOS interaction to the overall B7-
H2-mediated cytokine production by antibody blockade (Fig-
ure 4D). MIH12 partially decreased production of the majority
of cytokines, with more profound effects on TNF-a, IFN-g, IL-5,
IL-10, and IL-17A but less effective for IL-2 and IL-4. In contrast,
blockade by 9F.8A4 reduced all cytokine production to back-
ground (Figure 4D), indicating that B7-H2-CD28 costimulation
contributes to the cytokine production, which were exclusively
attributed to the B7-H2-ICOS interaction in the past.
Blockade of B7-H2-CD28 Interaction Inhibits Human
T Cell Activation
We sought to evaluate the role of the B7-H2-CD28 interaction in
more physiologically relevant models in vitro, including antigen-
specific memory T cell recall response and primary T cell
response to allogeneic antigens. In the first model, monocyte-
derived dendritic cells (DCs) were incubated with tetanus toxoid
(TT) to stimulate autologous peripheral T cells from adult individ-
uals who were previously immunized with tetanus vaccine.
The proliferation and IFN-g production of polyclonal memory
T cells in response to TT antigen were examined in the presence
of selected mAbs. First, we demonstrated that B7-H2 and B7-2
were highly expressed on DCs in these experiments (data not
shown). Whereas T cells proliferated vigorously to TT-DC stimu-
lation, inclusion of B7-H2 mAbMIH12 reduced TT-elicited prolif-
eration by approximately 20%, a small but significant inhibitionImmunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc. 733
Figure 4. B7-H2 Costimulation of Human T Cells through CD28
(A and B) B7-H2-CD28 interaction costimulates human T cell proliferation. Purified PBMCCD3+ T cells at 2.53 105/well were stimulated with immobilized human
CD3 mAb (OKT3) and B7-H2Ig or control Ig (ctl Ig).
(A) B7-H2 mAb (clone MIH12 or 9F.8A4) or control mouse Ig (ctl Ig) was added to block immobilized B7-H2Ig.
(B) CD28 mAb (CD28.6) and/or ICOS mAb (C398.4A) or control Ig was added to block B7-H2-mediated costimulation.
3HTdR was added during the final 6 hr of culture. Similar results were also obtained in two additional experiments with different donors.
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Figure 5. B7-H2-CD28 Interaction Is Impor-
tant for T Cell Activation
(A and B) B7-H2-CD28 interaction enhances
response of tetanus toxoid-specific memory
T cells.
(A) Monocyte-derived dendritic cells at 2.5 3
104/well and purified autologous T cells at 3 3
105/well were mixed together and incubated with
tetanus toxoid at the indicated concentrations for
5 days. Blocking mAbs against CD28 (clone
CD28.6), B7-H2 (clone MIH12 and 9F.8A4), or
control mouse Ig at 5 mg/ml was included
in soluble form at the beginning of the culture.
3HTdR was added during the final 16 hr of culture.
*p < 0.05.
(B) Interferon gamma concentration was mea-
sured in day 5 supernatants by BD (CBA) Human
Th1-Th2 cell cytokine kit and analyzed by FCAP
Array software. Each data point was an average of
three samples shown with standard deviations.
Similar results were also obtained in two additional
experiments with different donors.
(C andD) B7-H2-CD28 interaction promotes IFN-g
release in allogeneic T cell response.
(C) Monocyte-derived dendritic cells at 0, 1.253 104, 2.53 104/well, and purified allogeneic T cells at 33 105/well were mixed together. Blocking mAbs against
CD28 (clone CD28.6), B7-H2 (clone MIH12 and 9F.8A4), or control mouse Ig at 5 mg/ml was included in soluble form at the beginning of the culture for 5 days.
3HTdR was added during the final 16 hr of culture.
(D) Interferongammaconcentrationwasmeasured inday5supernatants byBD (CBA)HumanTh1-Th2cell cytokine kit andanalyzedbyFCAPArray software. Each
data point was an averageof three samples shownwith standard deviations. Similar resultswere also obtained in two additional experimentswith different donors.
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effect on IFN-g production: more than 80% IFN-g production
in the culture was suppressed (Figure 5B). Addition of CD28
blocking mAb (clone CD28.6, noncostimulatory), ICOS mAb
C398.4A, or B7-H2 mAb 9F.8A4 inhibited more than 50% of
proliferation and more than 90% of IFN-g production (Figures
5A and 5B). These findings indicate that both CD28 and ICOS
pathways are required for the proliferation and IFN-g production
of memory T cells in this setting. B7-H2-CD28 interaction,
although playing a minor role in the proliferation of memory
T cells, is critical for TT-induced IFN-g production from memory
T cells.
In the second model, DCs were used for stimulation of alloge-
neic T cells purified from human peripheral blood. In this culture
system, MIH12 also significantly suppressed IFN-g production
from allogeneic T cells (p < 0.05) (Figure 5D). Similar to TT
antigen-elicited memory T cell response, MIH12 was mainly
effective on control of IFN-g production but had only a small
effect on T cell growth (Figure 5C), perhaps because of the
weak IL-2-inducing capacity of B7-H2. Our results thus demon-
strated that endogenous B7-H2-CD28 interactions play a critical
role in promoting activation and cytokine production in human
T cells.(C) B7-H2-CD28 interaction promotes division of human T cells. Under the same
anti-human CD3 and B7-H2Ig. B7-H2 mAb (clone MIH12 or 9F.8A4) was used
a FACSCalibur flow cytometer. The average percentage of undivided T cell (n =
(D) B7-H2 costimulates cytokine production from human T cells through CD28. Pu
and B7-H2Ig as described in (A). MIH12, 9F.8A4, or control mouse Ig (ctl Ig) w
Cytokine concentrations were measured by BDCytometric Bead Array (CBA) hum
Flex set and analyzed by FCAP Array software. Each data point was an average o
obtained in two additional experiments with different donors.B7-H2-CD28 Interaction Upregulates Bcl-xL Expression
and Downregulates p27kip1
In addition to IL-2 production, another major difference between
CD28 and ICOS costimulation is that only CD28 signaling
induces increased production of the antiapoptotic molecule
Bcl-xL through its intracellular Src homology 2 binding domain
(SH2) (Boise et al., 1995; Parry et al., 2003). We next investigated
whether B7-H2-CD28 interaction could also stimulate Bcl-xL
protein expression. With suboptimal amounts of CD3 mAb,
B7-1g costimulated the expression of Bcl-xL in activated CD4+
T cells, whereas immobilized ICOS agonist mAb was unable to
upregulate Bcl-xL, as expected (Figure 6A). B7-H2Ig also
enhanced the expression of Bcl-xL, albeit to a lower degree
than B7-1Ig on day 2. Blockade of the B7-H2-CD28 interaction
by MIH12 partially suppressed Bcl-xL upregulation, whereas
9F.8A4 completely inhibited Bcl-xL expression (Figure 6B).
Similar to its effect in blocking T cell proliferation, CD28 mAb
CD28.6 also partially reduced B7-H2-induced Bcl-xL upregula-
tion, whereas soluble CTLA4 mAb 14D3 had no effect. Mean-
while, ICOS mAb C398.4A in soluble form inhibited the Bcl-xL
upregulation, suggesting that ICOS is important but not sufficient
for Bcl-xL expression. The complete inhibition was achieved
only when both B7-H2-CD28 and B7-H2-ICOS interactionscondition as (A), CFSE-labeled CD3+ T cells were stimulated with immobilized
to block coated B7-H2Ig. T cells were collected on day 4 and analyzed by
3) and 95% confidence intervals were given.
rified CD4+ T cells at 2.53 105/well were stimulated by immobilized CD3 mAb
as added to block B7-H2Ig. Supernatants were collected daily up to 3 days.
an T helper 1 cell and T helper 2 cell (Th1-Th2 cell) cytokine kit and CBA IL-17A
f three samples shown with their standard deviations. Similar results were also
Immunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc. 735
Figure 6. B7-H2-CD28 Interaction Pro-
motes Bcl-xL Expression and Downregu-
lates p27kip1 in Activated CD4+ T Cells
Purified CD4+ T cells at 3.5 3 105/well were
stimulated with immobilized human CD3 mAb
(0.1 mg/ml) and 5 mg/ml (A) control Ig (ctl Ig), B7-
1Ig, ICOS agonistic mAb (C398.4A), or (B and C)
B7-H2Ig. In some wells, B7-H2 mAb (MIH12 or
9F.8A4), CD28 mAb (CD28.6), CTLA-4 mAb
(14D3), ICOS mAb (C398.4A), or control mouse Ig
was used to block B7-H2Ig-mediated response.
(B) Activated T cells were harvested on day 2 and
day 3, intracellularly stained by Bcl-xL mAb, and
analyzed by flow cytometry.
(C) Activated T cells were harvested at 4 hr and
48 hr after activation. Cell lysates were prepared.
100 mg total protein per sample was loaded and
separated by 12% SDS-PAGE. The amount of
phosphorylated GSK-3 (harvested at 4 hr) and
p27kip1 (harvested at 48 hr) and b-actin were
determined by immunoblotting with respective
antibodies. b-actin was used as the loading
control.
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B7-H2 thus might require a cooperation of both CD28 and ICOS
signals. In summary, our results indicate that, in addition to the
induction of cytokines and T cell activation, B7-H2-CD28 inter-
action provides a crucial signal to enhance Bcl-xL expression.
It has been previously shown that CD28 promotes T cell prolif-
eration through downregulation of cyclin-dependent kinase
(CDK) inhibitor 1B (CDKN1B, p27kip1) (Appleman et al., 2002).
p27kip1 binds to and inhibits the activation of cyclin E-CDK2 or
cyclin D-CDK4 complex, resulting in cell cycle arrest (Sherr
and Roberts, 1999). As a result, the degradation of p27kip1 is
crucial for cell cycle progression. With a suboptimal amount of
CD3 mAb, immobilized B7-H2 downregulated p27kip1 protein
in human T cells on day2 (Figure 6C), which correlated with
increased cellular proliferation (Figure 4A) and upregulation of
Bcl-xL (Figure 6B). Because the degradation of p27kip1 is modu-
lated by phosphatidylinositol 3-kinase (PI3K)- and serine-threo-
nine kinase AKT(PKB)-dependent signaling pathways (Medema
et al., 2000), we further investigated the inactivation phosphory-
lation of glycogen synthase kinase-3 (GSK-3), one of AKT’s
downstream targets. Compared with control Ig group, GSK-3
phosphorylation wasmarkedly increased in B7-H2-costimulated
T cells 4 hr after activation (Figure 6C). More importantly, ICOS
and CD28 blockade with mAbs partially suppressed GSK-3
phosphorylation and increased the expression of p27kip1,
whereas CTLA4 mAb had no effect. Combined, these results
indicate increased expression of Bcl-xL, and downregulation of
p27kip1 might integrate TCR signal and B7-H2-CD28-mediated
costimulatory signal to promote survival and cell cycle progres-
sion in human T cells.
Human B7-H2 Costimulates the Activation of Murine
ICOS-Deficient T Cells via CD28
Blockade of ICOS or CD28 by mAbs are often incomplete and
this may jeopardize our further study of intracellular signaling736 Immunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc.events upon B7-H2-CD28 interaction. To exclude the effect of
residual ICOS or CD28, we took advantage of the cross-species
interactions of human B7-H2Ig with mouse ICOS and CD28
(Figure 2F) and employed ICOS genetically ablated T cells to
investigate whether B7-H2 could costimulate Icos/ T cells
via CD28. As shown in Figure 7A, human B7-H2 but not mouse
B7-H2 costimulated T cells from ICOS-deficient mice to prolif-
erate. Inclusion of a mouse CD28 mAb completely eliminated
the B7-H2-mediated effect (Figure 7B). In wild-type T cells,
human B7-H2 was also a much stronger costimulator than
mouse B7-H2 to promote wild-type mouse T cell to proliferate.
These findings validated the lack of B7-H2-CD28 interaction in
mouse system. Furthermore, B7-H2 could costimulate purified
CD4+Foxp3 naive T cells and CD4+Foxp3+ T regulatory cells
from ICOS-deficient mice in an IL-2-dependent fashion, as
shown by the fact that addition of IL-2-neutralizing mAb greatly
inhibited the growth of both cells (Figure S5).
Both CD28 and ICOS costimulation are known to activate
extracellular signal-regulated kinase (ERK) and PI3K- AKT-
dependent signaling cascades (Parry et al., 2003; Prasad et al.,
1994). Purified mouse CD4+ T cells were used to determine
the relative contribution of B7-H2-CD28 and B7-H2-ICOS
interactions in triggering ERK and AKT activation. Wild-type,
ICOS-deficient, or CD28-deficient mice were first activated
with anti-CD3 for 3 days. After resting for another 3 days in the
presence of IL-2, T cells were harvested and activated with
immobilized CD3 mAb and human B7-H2, mouse B7-1, or
control Ig proteins. As shown in Figure 7C, cell lysates were
prepared 5, 10, 30, and 60min after incubation and the activation
of ERK1, ERK2, and AKT was determined by immunoblots with
phosphorylation-specific mAbs. In wild-type T cells, simulta-
neous cross-linking of TCR and B7-1 or B7-H2 enhanced both
ERK andAKT phosphorylation as early as 10min after cross-link-
ing, whereas suboptimal CD3 cross-linking alone induced
minimal ERK and AKT phosphorylation. B7-1 and B7-H2 appear
Figure 7. B7-H2-CD28 Interaction Induces
Early Activation of ERK- and PI3K-AKT-
Dependent Pathways
(A) Purified native CD3+ T cells from wild-type or
ICOS-deficient mice at 3 3 105/well were stimu-
lated with immobilized 0.8 mg/ml mouse CD3 mAb
and 5 mg/ml human or mouse B7-H2Ig or control Ig
(ctl Ig).
(B) In some wells, mouse T cells were first incu-
bated with 5 mg/ml mouse CD28 mAb (37.51) or
control Ig for 15 min. After washing away unbound
mAb, T cells were added to 96-well plates. 3HTdR
was added during the final 6 hr of culture. Similar
results were also obtained in two additional
experiments. *p < 0.05.
(C) Purified mouse CD4+ T cells from wild-type,
ICOS-deficient, or CD28-deficient mice were
activated with 5 mg/ml immobilized anti-CD3 for
3 days and then rested for 3 days in the presence of
50 IU/ml rmIL-2. T cells were subsequently har-
vested and added into 96-well plates precoated
with 0.1 mg/ml CD3 mAb plus 5 mg/ml human
B7-H2, mouse B7-1, or control Ig proteins. Cells
were harvested at different time points as indi-
cated. Cell lysates were prepared. 100 mg total
protein per sample was loaded and separated by 12%SDS-PAGE. The amount of phosphorylated ERK andAKT protein were determined by immunoblotting with
phospho-specific antibodies (Thr202 and Tyr204 phospho-Erk1 and Erk2 or Ser473 phospho-Akt). Membranes were subsequently striped and reprobed with
antibodies against total ERK and AKT.
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wild-type T cells. However, in ICOS-deficient T cells, the kinetic
responses were quite different. Whereas B7-1 costimulation
induced patterns of ERK and AKT activation similar to that of
wild-type T cells, B7-H2 induced an earlier (5–10 min) ERK and
AKT phosphorylation followed by a quick reduction to back-
ground after 30 min. This observation indicates that B7-H2-
CD28 interaction induces a transient activation of the ERK and
AKT pathways at very early time points during T cell activation,
and sustained phosphorylation of ERK and AKT may require
B7-H2-ICOS interaction. In contrast, we did not observe an
earlier (5–10 min) response of ERK and AKT phosphorylation in
wild-type T cells. This may be due to the competition of ICOS
and CD28 for B7-H2 binding because the B7-H2-ICOS interac-
tion has a much higher affinity. In Cd28/ T cells, B7-1-depen-
dent AKT and ERK phosphorylations were completely abolished.
Meanwhile, B7-H2-mediated activation of AKT and ERK showed
patterns similar to wild-type T cells, indicating that the B7-H2-
ICOS interaction dictates B7-H2-induced AKT and ERK activa-
tion in wild-type T cells.
Finally, we compared the cytokine profile of CD4 T cells
from wild-type and ICOS-deficient mice in response to human
B7-H2 costimulation (Figure S6). Consistent with our observa-
tions in human T cells, B7-H2 costimulation enhanced the
production of TNF-a, IFN-g, and IL-17A from Icos/ mouse
T cells, albeit in much lower amounts than in wild-type T cells.
B7-H2-CD28 interaction also induced a low IL-2 secretion from
Icos/ T cells. On the other hand, mouse T cells produced
low basal amounts of IL-4 and IL-10 upon B7-H2 costimulation,
which was markedly different from human T cell responses
(Figure S4).
In summary, we confirmed the functional interaction of B7-H2-
CD28 in mouse ICOS-deficient T cells and found that B7-H2-CD28 interaction activated ERK- and AKT-dependent signaling
pathways.
DISCUSSION
In this report, we have presented evidence that B7-H2 is a costi-
mulatory ligand for CD28. The noncompeting nature of B7-H2
and B7-1 or B7-2 for binding CD28 suggests that these ligands
could work independently, simultaneously, and even synergisti-
cally to provide maximal CD28 costimulation for T cells. Our
findings also provide amolecular basis for the crosstalk between
CD28, CTLA-4, and ICOS pathways, which may help explain the
functional redundancy of CD28 and ICOS costimulation.
Because of the lack of this interaction in mouse, our discovery
also warrants careful re-evaluation of knowledge previously
acquired from murine models.
To identify additional cell surface interactions, we employed
a receptor array system with high throughput capacity. The
human genome contains 5000 genes predicted to encode
cell membrane proteins (Lander et al., 2001; Venter et al.,
2001). However, fewer than 1000 proteins have been identified
to have counter-receptors, largely because of the lack of sensi-
tive and robust methods. Many cell surface proteins or their
mRNA are in low abundance and their expressions vary accord-
ing to environmental cues. In addition, themajority of cell surface
molecular interactions are fast-on-and-fast-off with low affini-
ties. Although this feature may allowmaximal control of signaling
and effector function in immune responses, it increases the diffi-
culty of identifying cell surface interactions by conventional
methods, including expression cloning and protein microse-
quencing. The cellular detection system allows us to scan only
the bottom of a microplate well at a depth of 100 mm, avoiding
background from nonbinding secondary antibody in solution.Immunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc. 737
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washing steps. High expression of individual protein on cell
surface by 293T cell transient transfection also vastly increases
the avidity of its interaction with counter-receptor. An overnight
incubation without any disturbing wash procedure further helps
to stabilize weak interactions. Combining increased avidity and
a highly sensitive detection system, this receptor array enabled
us to identify receptor-ligand interactions that are otherwise
undetectable on primary cells by other conventional methods,
including flow cytometry. For example, the recently published
B7-1-B7-H1 interaction with the binding affinity around 1 mM
(Butte et al., 2007) could be easily detected in our screening
system. Therefore, our receptor array screening system repre-
sents a promising approach to discover additional molecular
interactions on the cell surface. With the expansion of this array
to include all plasma membrane proteins, this system could be
utilized to identify virtually any protein interactions on cell
surface.
It was reported that monomeric B7-H2 binds to ICOS but not
CD28 and CTLA4, whereas tetrameric B7-H2 bound CD28 and
CTLA-4 at 25C but not 37C by surface plasmon resonance
(SPR) (Brodie et al., 2000). Here we identified B7-H2-CD28
interactions in a cell-base system at 37C. We also confirmed
these interactions by dimeric B7-H2, CD28, and CTLA-4 fusion
proteins at both 25C and 37C in SPR. Flow cytometry analysis
with 293T cell transfectants and fusion proteins performed at
room temperature and 37C (data not shown) further validated
B7-H2 interactions with CD28 and CTLA-4. The discrepancy of
our results and those of Brodie et al. (2000) may be due to the
different forms of fusion proteins (monomeric versus dimeric)
used in respective experiments.
B7-H2 is expressed constitutively by hematopoietic and is
inducible on nonhematopoietic cells in peripheral organs,
whereas B7-1 and B7-2 are largely inducible molecules
expressed on selective antigen-presenting cells. This distinct
expression pattern of three ligands may enable them to regulate
T cell responses through CD28 in spatially and temporally diver-
gent settings. B7-H2-CD28 interaction may be particularly
important when T cells migrate to peripheral tissues where
B7-1 and B7-2 expression is limited. CD28 is constitutively
expressed on naive T cells whereas ICOS and CTLA-4 are induc-
ible upon antigen stimulation (Hutloff et al., 1999). Therefore, the
role of B7-H2 on naive T cells should be primarily promoting
T cell activation through CD28. B7-H2’s role on activated
T cells, however, should be predominantly costimulatory medi-
ated via ICOS, because ICOS has a higher affinity for B7-H2
than CD28 and CTLA-4. The role of B7-H2-CTLA4 interaction
remains to be explored.
Competitive binding experiments suggest that CD28 utilizes
different interfaces to interact with B7-H2 compared with B7-1
and B7-2. Previous studies show that CD28 and CTLA-4 interact
with B7-1 and B7-2 through a highly conservedMYPPPYmotif in
the CDR3-like loop (Harper et al., 1991; Peach et al., 1994).
Therefore, it is highly likely that B7-H2 is a nonredundant ligand
and could work in the presence of B7-1 and B7-2 to deliver
synergistic or complementary costimulatory signals. Our find-
ings thus reveal an additional feature of CD28 costimulation:
more than one interface on a costimulatory receptor is available
for different ligands to engage. This mechanism may be particu-738 Immunity 34, 729–740, May 27, 2011 ª2011 Elsevier Inc.larly important when one of these receptors is deficient. Human
ICOS deficiency because of deletion mutations causes no
major impairment on T cell functions (Bossaller et al., 2006;
Grimbacher et al., 2003; Warnatz et al., 2006) with few excep-
tions (Takahashi et al., 2009). In contrast, mice with a genetic
ablation of Icos have reduced T cell activation, lower IL-4 and
IL-10 production, and a decrease in the memory T cell popula-
tion (Burmeister et al., 2008; Dong et al., 2001). Because B7-
H2-CD28 interaction is not conserved inmouse, our results imply
that B7-H2-CD28 interaction may compensate T cell function in
the absence of ICOS in human.
Our mutagenesis study indicates that B7-H2 uses similar but
not identical binding sites to interact with CD28 and CTLA-4.
This finding laid a theoretic basis for differential blockade of
these interactions with antibody. MIH12, a mAb selectively
blocking B7-H2 interactions with CD28 and CTLA-4 but not
ICOS, suppressed T cell proliferation in the B7-H2-mediated
costimulation in vitro and had a strong inhibitory effect on
TNF-a, IFN-g, IL-5, IL-10, and IL-17A production. B7-H2-CD28
blockade also significantly suppressed IFN-g production but
was less effective on TT antigen-elicited memory and allogeneic
T cell responses. These findings may be due to the weak ability
of B7-H2 to costimulate IL-2 production.
The mechanism underlying B7-H2 as a weak stimulator of IL-2
upon engaging CD28 remains to be elucidated. It is possible
that upregulated ICOS after activation competes with CD28
for B7-H2 binding, because the ICOS-B7-H2 interaction has
a higher affinity than CD28-B7-H2. In addition, B7-H2 engages
CD28 at amore discrete domain than B7-1 does andwith a lower
affinity.
Besides cytokine production, both B7-H2 and B7-1 promote
Bcl-xL expression in activated CD4+ T cells. This is in sharp
contrast to the observation that only CD28 but not ICOS agonist
mAb induces Bcl-xL. Inclusion of MIH12 or CD28 mAbs reduced
Bcl-xL expression, indicating that B7-H2-CD28 interaction is
important for B7-H2-mediated Bcl-xL induction. These results
also indicate that different extracellular domains onCD28 govern
distinctive cellular functions, including IL-2 production, Bcl-xL
induction, and the generation of other cytokines. In addition,
we found that B7-H2 costimulation also leads to the downregu-
lation of the cell cycle inhibitor, p27kip1, possibly mediated
through the PI3K-AKT signaling cascades. CD28 blockade by
mAb partially inhibited GSK-3 phosphorylation and p27kip1
degradation, implicating an active role of the B7-H2-CD28 inter-
action in these pathways. Thus, Bcl-xL and p27kip1 might be
important links integrating TCR and B7-H2-CD28-mediated
signals to survival and cellular proliferation. This notion is sup-
ported by the study with ICOS-deficient mouse T cells in which
B7-H2 induced an early ERK and AKT phosphorylation in the
absence of ICOS, whereas B7-H2 promoted and sustained
ERK and AKT phosphorylation in wild-type T cells.
Our findings also warrant re-evaluation of CD28 and ICOS
pathways as targets for immunotherapeutic manipulation. For
example, the immunosuppressive effect of CTLA-4Ig (Abata-
cept) could be interpreted, at least partially, as interference of
B7-H2-CD28 interaction, because a high dose of CTLA-4Ig will
compete with CD28 for B7-H2 binding. All together, our findings
provide important information for the current effort in manipu-
lating these pathways for treating human diseases.
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Plasmids, Fusion Proteins, and Monoclonal Antibodies
Human full-length plasma membrane genes (>2000) were purchased from
Open Biosystems (Huntsville, AL) or cloned into mammalian expression vector
individually. Human and mouse fusion proteins were purchased from R&D
Systems (Minneapolis, MN) or expressed in 293T cell and purified by Protein
A columns. Antibodies used in flow cytometry and in vitro studies were
purchased from BD Biosciences (San Jose, CA), BioLegend (San Diego,
CA), or eBioscience (San Diego, CA). Anti-human Ig FMAT bluewas purchased
from Applied Biosystems (Foster City, CA). Western blot antibodies were all
purchased from Cell Signaling (Danvers, MA). Detailed information of each
antibody can be found in Supplemental Experimental Procedures online.
Animals
C57BL/6 (B6) mice were purchased from the National Cancer Institute
(Frederick, MD). Cd28/ and Icos/mice in B6 background were purchased
from The Jackson Laboratory (Bar Harbor, ME). Age-matched 6- to 8-week-
old mice were used for all experiments. All mouse protocols were in accor-
dance with NIH guidelines and were approved by the Animal Care and Use
Committee of the Johns Hopkins University School of Medicine and Yale
University School of Medicine.
High-Throughput Transfection and Screening
Plasmids with human transmembrane genes were diluted by OPTI-MEM
media and placed individually into five 384-well plates at 60 ng/well. 0.15 ml
Lipofectamine 2000 was added to each well and mixed with plasmids for
30 min. Subsequently, 10,000 293T cells were added to each well to perform
transient transfection. 8 hr after transfection, 50 ng human CD28Ig and 50 ng
anti-human Ig FMAT blue secondary antibody were added into each well. The
plates were read 24 hr after transfection by the Applied Biosystems 8200
cellular detection system and analyzed by CDS 8200 software.
T Cell Costimulation Assay
Human peripheral mononuclear cells (PBMCs) from healthy donors were
purchased from Research Blood Components (Brighton, MA). T cells were
negatively selected from PBMCs and purified with a human pan-T cell selec-
tion kit or a human CD4 T cell selection kit (Miltenyi Biotec, Auburn, CA).
Human CD3 mAb (OKT3) was precoated in 96-well plates at the indicated
concentrations. B7-H2Ig or isotype-matched control Ig at 5 mg/ml was also
immobilized in the wells. Purified human T cells were added into each well at
2.5 3 105/well and cultured for 3 days. In some experiments, B7-H2 mAb,
MIH12, or 9F.8A4 was added at 10 mg/ml at the beginning of culture, and
unbound mAbs were washed away by media before addition of T cells. To
block CD28, T cells were first incubated with 5 mg/ml human CD28 mAb
(CD28.6) for 15 min. T cells were then added to 96-well plates after washing
away unbound CD28.6. For ICOS blockade, anti-human ICOS (C398.4A)
was added to the culture at 10 mg/ml in soluble form. 3HTdR was added during
the final 6 hr of culture. 3H-TdR incorporation was counted with a MicroBeta
Trilux liquid scintillation counter (PerkinElmer, Waltham, MA). T cell costimula-
tion assays were repeated with three different donors.
Bcl-xL Intracellular Staining
Mouse anti-human Bcl-xL PE (clone 7B2.5) was purchased from Southern
Biotech (Birmingham, AL). Activated human CD4 T cells were harvested and
washed with cold PBS. Intracellular staining for Bcl-xL was performed accord-
ing to manufacturer’s protocol (Cytofix/Cytoperm, BD).
T Cell Lysate Preparation and Immunoblot
T cells were harvested at indicated time after activation. Immunoblot detection
was performed with SuperSignal West femto kit from Thermo Scientific.
Statistics
T cell proliferation was measured by thymidine incorporation and the amount
of IFN-g in the supernatant were compared between control Ig and blocking
antibody groups via 2-tailed Student’s t test. p values less than 0.05 were
considered statistically significant. The error bars in figures represent standard
deviation (SD).SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and one table and can be found with this article online at doi:
10.1016/j.immuni.2011.03.014.
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